Poland· PL-100484838
Polcylin
A phenoxymethylpenicillin product containing phenoxymetylopenicillinum potassium, registered in Poland by Tarchomińskie Zakłady Farmaceutyczne "Polfa" S.A.. The same ATC class is registered in 16 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Phenoxymethylpenicillin is registered in 16 of 19 countries.
Countries holding a registration under ATC J01CE02 (phenoxymethylpenicillin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Phenoxymethylpenicillin · ATC J01CE02
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Phenoxymetylopenicillinum potassium
- Manufacturer
- Tarchomińskie Zakłady Farmaceutyczne "Polfa" S.A.
- Country
- Poland (PL)
- ATC code
- J01CE02
- ATC class
- Phenoxymethylpenicillin
- Defined daily dose
- 2 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
2 priced- gtin059040160132051 but. 125 mlPLN 37.27
- gtin059040160132121 but. 60 mlPLN 19.1
- gtin05904016013199
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
43 interactions on record for phenoxymethylpenicillin.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Phenoxymethylpenicillin · interactions on record
43 records
- 3 severe
- 19 moderate
- 2 minor
- 19 info
Most severe, free to view
- MethotrexateL01BA01severe
- MethotrexateL04AX03severe
- MethotrexatM01CX01severe
- Sodium picosulfateA06AB08moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under J01CE02
Phenoxymethylpenicillin, as other registers publish it.
- FinlandAcipen SolutabYamanouchi Europe B.V.
- FinlandAcipen SolutabYamanouchi Europe B.V.
- FinlandAcipen SolutabYamanouchi Europe B.V.
- FinlandAcipen SolutabYamanouchi Europe B.V.
- FinlandAcipen SolutabYamanouchi Europe B.V.
- NetherlandsAcipen-V 250 mg, harde capsulesACE Pharmaceuticals B.V.
- NorwayActacillinTeva B.V.
- NorwayActacillinTeva B.V.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e9f97c87-cb08-4b46-88e9-8c6812b47af1 GET /v1/drugs/e9f97c87-cb08-4b46-88e9-8c6812b47af1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Granulat do sporządzania zawiesiny doustnej",
"source": "urpl",
"strength": "100 mg/ml",
"packaging": "05904016013212 ¦ Rp ¦ 150838\n1 butelka 60 ml\n05904016013199 ¦ Rp ¦ 150839\n1 butelka 200 ml\n05904016013205 ¦ Rp ¦ 150840\n1 butelka 125 ml",
"substance": "Phenoxymethylpenicillinum kalicum 100 mg/ml",
"common_name": "Phenoxymetylopenicillinum potassium",
"pl_product_id": "100484838",
"pozwolenie_nr": "27945",
"auth_procedure": "MRP",
"authorisation_validity": "Bezterminowe"
}See everything about phenoxymethylpenicillin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.